サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1564921

B型肝炎ワクチンの世界市場

Hepatitis B Vaccines

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
B型肝炎ワクチンの世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

B型肝炎ワクチンの世界市場は2030年までに39億米ドルに到達

2023年に29億米ドルと推定されるB型肝炎ワクチンの世界市場は、2023年から2030年にかけてCAGR 4.3％で成長し、2030年には39億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである成人用アプリケーションは、CAGR 4.2%を記録し、分析期間終了時には27億米ドルに達すると予測されます。小児用アプリケーションの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は7億8,130万米ドルと推定、中国はCAGR6.8％で成長すると予測

米国のB型肝炎ワクチン市場は、2023年に7億8,130万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 6.8%を牽引し、2030年までに8億1,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と3.6%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界のB型肝炎ワクチン市場- 主要動向と促進要因のまとめ

B型肝炎ワクチンは世界の肝臓衛生の要か？

B型肝炎ワクチンは、最も広く蔓延し、死に至る可能性のあるウイルス感染症を予防するための重要なツールですが、なぜこれらのワクチンが必要不可欠なのでしょうか？B型肝炎（HBV）は肝臓を攻撃するウイルス感染症で、肝硬変や肝がんなどの急性および慢性の肝疾患を引き起こします。血液などの感染性体液に接触することで感染するため、世界の健康上の重大な問題となっています。慢性HBV感染症は数十年間持続する可能性があり、多くの場合症状はないが、時間の経過とともに重篤な肝障害や合併症を引き起こす可能性があります。世界保健機関（WHO）の推計によると、2億9,600万人以上の人々が慢性B型肝炎に罹患しており、毎年82万人近くがB型肝炎による合併症が原因で死亡しています。

B型肝炎ワクチンは、HBV感染とその結果の予防に非常に効果的です。B型肝炎ワクチンは、免疫系を刺激してB型肝炎ウイルスに対する抗体を産生させ、B型肝炎ウイルスに感染しても感染しないようにします。このワクチンは数回に分けて接種され、利用可能なワクチンの中で最も効果的なもの1つと考えられており、ほとんどの人に長期にわたる免疫が得られます。実際、B型肝炎のワクチン接種は、出生時のすべての乳幼児や、ヘルスケア従事者や慢性肝疾患患者を含むリスクの高い成人に対して推奨されています。ワクチン接種が普及すれば、各国は新たなHBV感染の発生を大幅に減らすことができ、最終的には肝がんや肝硬変といったB型慢性肝炎の長期合併症を予防することができます。

技術はB型肝炎ワクチン開発をどのように進歩させたか？

技術の進歩により、B型肝炎ワクチンの安全性、有効性、入手しやすさが大幅に改善され、より有効で広く利用できるようになりました。第一世代のB型肝炎ワクチンは、感染者の血漿に由来していましたが、この方法は血液を介した感染に関連するリスクがあり、製造コストも高額でした。1980年代に組換えDNA技術が導入されると、ワクチン製造に革命が起こり、現在標準となっている組換え型B型肝炎ワクチンが開発されました。これらのワクチンは、B型肝炎表面抗原（HBsAg）の遺伝子を酵母などの細胞に挿入し、抗原を産生させることで製造されます。この抗原を採取してワクチンを作るため、ヒトの血液製剤を必要とせず、非常に効果的で安全な予防接種の方法が提供されます。

B型肝炎、ジフテリア、破傷風、百日咳（DTaP）に対する予防を組み合わせたワクチンなどは、小児期の予防接種プログラムにおいて特に有用であり、包括的な予防を提供しながらも必要な注射の回数を減らすことができます。これは、物流上の課題によりワクチン接種が困難な低資源環境において特に重要です。

さらに、アジュバント（免疫反応を高めるためにワクチンに添加される物質）の研究により、B型肝炎ワクチンの効果は向上しています。最近のB型肝炎ワクチンには、体の免疫反応を高めるアジュバントが含まれていることが多く、より強力で長持ちする免疫が保証されています。また、現在では、患者のコンプライアンスや利用しやすさを向上させるため、より少ない用量で済むように処方されているワクチンもあります。マイクロニードルパッチのような新しい送達システムの使用も、特に従来の注射方法が困難な環境において、ワクチン投与をより簡単かつ低侵襲にするために研究されています。このような技術革新は、B型肝炎ワクチンの有効性を高めるだけでなく、世界の予防接種活動においてより実用的でスケーラブルなものとなっています。

なぜB型肝炎ワクチンは世界ヘルスにとって重要なのか？

B型肝炎ワクチンは、世界的に肝臓病やがんの主要な原因となっているウイルスに対する効果的な防御を提供するため、世界ヘルスにとって極めて重要です。B型肝炎は感染力が強く、血液や性的接触、出産時に母子感染する可能性があります。ワクチン接種を受けなければ、B型肝炎の母親から生まれた乳児は慢性感染者となるリスクが高く、生涯にわたって重篤な肝疾患を患うリスクがあります。生後24時間以内に新生児にワクチンを接種することは、母子感染を予防する最も効果的な方法のひとつであり、公衆衛生の脅威としてのB型肝炎を撲滅するための世界の取り組みの要となっています。

B型肝炎が流行している地域、特にアフリカとアジアの一部では、この病気の負担は計り知れないです。多くの人は小児期に感染し、ウイルスは何十年も体内に留まり、肝硬変や肝がんなどの慢性肝疾患を引き起こすことが多いです。ワクチン接種がなければ、これらの地域は莫大なヘルスケアコストとHBV関連合併症による生命損失に直面することになります。B型肝炎ワクチンを広く接種することで、慢性HBV感染率や肝臓がんなどの関連疾患の発生率が大幅に減少することが示されています。普遍的なB型肝炎ワクチン接種プログラムを実施した国々では、ウイルスとその合併症の有病率が劇的に減少しており、公衆衛生を守る上でワクチンの役割が強調されています。

B型肝炎ワクチンは、ヘルスケア従事者、慢性肝疾患患者、感染した血液や体液にさらされる可能性のある人など、脆弱な人々を守るためにも極めて重要です。特にヘルスケア従事者は、職業上HBVに暴露されるリスクがあり、ワクチン接種は感染に対する不可欠な予防策となります。C型肝炎や肝硬変を含む慢性肝疾患の患者にとっては、B型肝炎からの予防が加わることで、さらなる肝障害を防ぎ、肝不全のリスクを軽減することができます。全体的に見て、B型肝炎ワクチンは個人を危険なウイルス感染から守るだけでなく、肝がん発生率の低下と世界的に健康転帰を改善することを目指した、より広範な公衆衛生の取り組みにも貢献します。

B型肝炎ワクチン市場の成長を促進する要因は何か？

B型肝炎ワクチン市場の成長は、疾患に対する認知度の向上、ワクチン接種プログラムの拡大、ワクチン開発の進歩など、いくつかの主な要因によって牽引されています。主な要因のひとつは、肝疾患や肝がんの主要な原因であるB型肝炎の世界の負担に対する認識の高まりです。各国政府や公衆衛生機関は、特にB型肝炎ウイルスが流行している地域において、予防接種の普及を通じてB型肝炎ウイルスの発症を減らす努力を強めています。世界保健機関（WHO）は、公衆衛生上の脅威としてのウイルス性肝炎を2030年までに撲滅するという目標を掲げており、そのために予防接種プログラムへの投資を増やし、B型肝炎ワクチン接種の重要性に関する認識を高めるため、より積極的な公衆衛生キャンペーンを展開しています。

特に低・中所得国におけるワクチン接種率の拡大も、市場を牽引する重要な要因です。世界肝炎計画やワクチン同盟Gaviのような国際的イニシアチブは、十分なサービスを受けていない地域におけるB型肝炎ワクチンへのアクセス拡大に重要な役割を果たしています。これらのプログラムは、各国が普遍的な新生児ワクチン接種を実施し、HBV感染リスクの高い成人もワクチン接種を受けられるようにするための資金援助や後方支援を行っています。B型肝炎ワクチンの定期接種を国の予防接種スケジュールとして採用する国が増えるにつれ、B型肝炎ワクチンの需要は増加の一途をたどっています。

ワクチン開発における技術的進歩も市場の成長に寄与しています。組換えワクチンの開発により、B型肝炎の予防接種はより安全で効果的なものとなり、また、混合ワクチンの出現により、小児および成人集団における予防接種の利便性が向上しています。1回の接種で複数の疾病を予防するこれらの混合ワクチンは、物流上の課題がワクチン接種の妨げとなり得る大規模な予防接種プログラムにおいて特に有用です。さらに、マイクロニードルパッチや注射針不要の注射器など、ワクチン投与における技術革新は、特に遠隔地や資源の乏しい環境において、B型肝炎ワクチンの利用しやすさをさらに向上させる可能性があります。

最後に、B型肝炎と肝臓がんとの関連性に対する一般市民の意識の高まりが、ワクチン接種の需要を後押ししています。予防ヘルスケアへの関心が高まるにつれ、B型慢性肝炎の最も深刻な合併症の一つである肝がんの発症リスクを低減するためにHBVワクチンを接種することの長期的なメリットが、個人や医療提供者に認識されるようになっています。公衆衛生機関がより広範なワクチン接種とB型肝炎の撲滅を提唱し続ける中、B型肝炎ワクチンの市場は着実に成長し、世界の肝臓の健康と疾病予防における重要なツールとしてのワクチンの役割が強化されると予想されます。

調査対象企業の例（注目の14社）

  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Binnopharm Group LLC
  • Biokangtai
  • CSL Ltd.
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering Co., Ltd.
  • Merck & Co., Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP12349

Global Hepatitis B Vaccines Market to Reach US$3.9 Billion by 2030

The global market for Hepatitis B Vaccines estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Adult Application, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Pediatric Application segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$781.3 Million While China is Forecast to Grow at 6.8% CAGR

The Hepatitis B Vaccines market in the U.S. is estimated at US$781.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$814.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Hepatitis B Vaccines Market - Key Trends and Drivers Summarized

Are Hepatitis B Vaccines the Cornerstone of Global Liver Health?

Hepatitis B vaccines are critical tools in preventing one of the most widespread and potentially deadly viral infections, but why are these vaccines so essential? Hepatitis B (HBV) is a viral infection that attacks the liver, leading to both acute and chronic liver disease, including cirrhosis and liver cancer. It is transmitted through contact with infectious body fluids, such as blood, making it a significant global health concern. Chronic HBV infection can persist for decades, often without symptoms, but can lead to severe liver damage and complications over time. The World Health Organization (WHO) estimates that over 296 million people are living with chronic hepatitis B, with nearly 820,000 deaths each year attributed to complications from the disease.

The hepatitis B vaccine is highly effective in preventing HBV infection and its consequences. It works by stimulating the immune system to produce antibodies against the hepatitis B virus, thereby protecting individuals from becoming infected if they are exposed to the virus. The vaccine is administered in a series of shots and is considered one of the most effective vaccines available, providing long-lasting immunity in most individuals. In fact, vaccination against hepatitis B is recommended for all infants at birth, as well as for high-risk adults, including healthcare workers and individuals with chronic liver disease. With widespread vaccination, countries can drastically reduce the incidence of new HBV infections, ultimately preventing the long-term complications of chronic hepatitis B, such as liver cancer and cirrhosis.

How Has Technology Advanced Hepatitis B Vaccine Development?

Technological advancements have significantly improved the safety, efficacy, and accessibility of hepatitis B vaccines, making them more effective and widely available. The first-generation hepatitis B vaccines were derived from the blood plasma of infected individuals, but this method posed risks related to blood-borne infections and was expensive to produce. The introduction of recombinant DNA technology in the 1980s revolutionized vaccine production, leading to the development of recombinant hepatitis B vaccines, which are now the standard. These vaccines are made by inserting the gene for the hepatitis B surface antigen (HBsAg) into yeast or other cells, which then produce the antigen. The antigen is harvested and used to create the vaccine, offering a highly effective and safe method for immunization without the need for human blood products.

Further advancements have led to the creation of combination vaccines that protect against multiple diseases, including hepatitis B. These vaccines, such as those that combine protection against hepatitis B, diphtheria, tetanus, and whooping cough (DTaP), are particularly useful in childhood immunization programs, reducing the number of injections required while still providing comprehensive protection. This is especially important in low-resource settings, where logistical challenges can make vaccine delivery difficult.

In addition, research into adjuvants—substances added to vaccines to enhance the immune response—has improved the effectiveness of hepatitis B vaccines. Modern hepatitis B vaccines often include adjuvants that boost the body’s immune response, ensuring stronger and longer-lasting immunity. Some vaccines are also now formulated to require fewer doses, improving patient compliance and accessibility. The use of novel delivery systems, such as microneedle patches, is also being explored to make vaccine administration easier and less invasive, especially in settings where traditional injection methods may be challenging. These technological innovations have not only enhanced the effectiveness of hepatitis B vaccines but have also made them more practical and scalable for use in global immunization efforts.

Why Are Hepatitis B Vaccines Critical for Global Health?

Hepatitis B vaccines are critical for global health because they provide effective protection against a virus that is a leading cause of liver disease and cancer worldwide. Hepatitis B is highly contagious and can be transmitted through blood, sexual contact, and from mother to child during childbirth. Without vaccination, infants born to mothers with hepatitis B have a high risk of becoming chronically infected, leading to a lifetime risk of serious liver disease. Vaccinating newborns within the first 24 hours of life is one of the most effective ways to prevent mother-to-child transmission, and it is a cornerstone of global efforts to eliminate hepatitis B as a public health threat.

In regions where hepatitis B is endemic, particularly in parts of Africa and Asia, the burden of the disease is immense. Many individuals are infected during childhood, and the virus can remain in the body for decades, often leading to chronic liver conditions such as cirrhosis and liver cancer. Without vaccination, these regions face enormous healthcare costs and loss of life due to HBV-related complications. Hepatitis B vaccines, when administered widely, have been shown to significantly reduce the rates of chronic HBV infection and associated diseases, including liver cancer. Countries that have implemented universal hepatitis B vaccination programs have seen dramatic reductions in the prevalence of the virus and its complications, underscoring the vaccine's role in protecting public health.

Hepatitis B vaccines are also crucial for protecting vulnerable populations, such as healthcare workers, people with chronic liver disease, and individuals who may be exposed to infected blood or bodily fluids. Healthcare professionals, in particular, are at risk of occupational exposure to HBV, and vaccination provides an essential safeguard against infection. For individuals with chronic liver disease, including those with hepatitis C or cirrhosis, the added protection from hepatitis B can prevent further liver damage and reduce the risk of liver failure. Overall, the hepatitis B vaccine not only protects individuals from a dangerous viral infection but also contributes to broader public health efforts aimed at reducing liver cancer rates and improving health outcomes globally.

What Factors Are Driving the Growth of the Hepatitis B Vaccine Market?

The growth of the hepatitis B vaccine market is driven by several key factors, including increased awareness of the disease, expanded vaccination programs, and advancements in vaccine development. One of the primary drivers is the growing recognition of the global burden of hepatitis B, which is a leading cause of liver disease and liver cancer. Governments and public health organizations are intensifying efforts to reduce the incidence of HBV through widespread immunization, particularly in regions where the virus is endemic. The World Health Organization (WHO) has set targets for the elimination of viral hepatitis as a public health threat by 2030, which has led to increased investment in vaccination programs and more aggressive public health campaigns to raise awareness about the importance of hepatitis B vaccination.

Expanded vaccination coverage, especially in low- and middle-income countries, is another significant factor driving the market. International initiatives like the Global Hepatitis Programme and Gavi, the Vaccine Alliance, have played key roles in increasing access to the hepatitis B vaccine in underserved regions. These programs provide funding and logistical support to help countries implement universal newborn vaccination and ensure that adults at high risk of HBV infection can also access the vaccine. As more countries adopt routine hepatitis B vaccination as part of their national immunization schedules, the demand for hepatitis B vaccines continues to rise.

Technological advancements in vaccine development have also contributed to market growth. The development of recombinant vaccines has made hepatitis B immunization safer and more effective, while the emergence of combination vaccines has improved the convenience of delivering immunizations in pediatric and adult populations. These combination vaccines, which protect against multiple diseases with a single shot, are particularly valuable in large-scale immunization programs where logistical challenges can hinder vaccine administration. Additionally, innovations in vaccine delivery, such as microneedle patches or needle-free injectors, could further enhance the accessibility of hepatitis B vaccines, particularly in remote or resource-poor settings.

Lastly, growing public awareness of the link between hepatitis B and liver cancer is driving demand for vaccination. With increasing focus on preventive healthcare, individuals and healthcare providers are recognizing the long-term benefits of vaccinating against HBV to reduce the risk of developing liver cancer, one of the most serious complications of chronic hepatitis B. This heightened awareness is encouraging more people to get vaccinated, including adults who may have been overlooked during childhood immunization campaigns. As public health agencies continue to advocate for broader vaccination coverage and the elimination of hepatitis B, the market for hepatitis B vaccines is expected to grow steadily, reinforcing the vaccine’s role as a critical tool in global liver health and disease prevention.

Select Competitors (Total 14 Featured) -

  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Binnopharm Group LLC
  • Biokangtai
  • CSL Ltd.
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering Co., Ltd.
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hepatitis B Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in National Immunization Programs Expands Addressable Market for Hepatitis B Vaccines
    • Growth in Newborn and Pediatric Vaccination Programs Expands Market Opportunities
    • Role of Hepatitis B Vaccines in Preventing Liver Cancer and Chronic Hepatitis Sets Stage for Market Growth
    • Combination Vaccines and Single-dose Solutions Expands Market Potential
    • Increasing Focus on Booster Vaccination Programs for High-risk Populations Drives Demand
    • Growth in Travel and Occupational Health Vaccination Expands Addressable Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis B Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis B Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Hepatitis B Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Italy 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UK 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Spain 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Russia 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Hepatitis B Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Australia 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: India 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: India 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: South Korea 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Hepatitis B Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Latin America 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Argentina 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Brazil 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Mexico 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Rest of Latin America 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Hepatitis B Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Middle East 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Iran 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Israel 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Saudi Arabia 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: UAE 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Rest of Middle East 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Africa 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION